Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Canakinumab in Rheumatoid Arthritis
NCT00554606Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2007
- Primary completion
- Aug 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of canakinumab in rheumatoid arthritis (RA), sponsored by Novartis. Primary endpoint: Number of Participants With Adverse Events and Serious Adverse Events at Week 60. Started Oct 2007; status: completed.
02
Drugs
canakinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00554606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00554606.